Smoking cessation for chronic obstructive pulmonary disease (Review)

van der Meer RM, Wagena E, Ostelo RWJG, Jacobs AJE, van Schayck OP

This is a reprint of a Cochrane review, prepared and maintained by The Cochrane Collaboration and published in The Cochrane Library 2009, Issue 1

http://www.thecochranelibrary.com
# Table of Contents

<table>
<thead>
<tr>
<th>Section</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Header</td>
<td>1</td>
</tr>
<tr>
<td>Abstract</td>
<td>1</td>
</tr>
<tr>
<td>Plain Language Summary</td>
<td>2</td>
</tr>
<tr>
<td>Background</td>
<td>2</td>
</tr>
<tr>
<td>Objectives</td>
<td>3</td>
</tr>
<tr>
<td>Methods</td>
<td>3</td>
</tr>
<tr>
<td>Results</td>
<td>5</td>
</tr>
<tr>
<td>Discussion</td>
<td>10</td>
</tr>
<tr>
<td>Authors’ Conclusions</td>
<td>12</td>
</tr>
<tr>
<td>Acknowledgements</td>
<td>12</td>
</tr>
<tr>
<td>References</td>
<td>12</td>
</tr>
<tr>
<td>Characteristics of Studies</td>
<td>15</td>
</tr>
<tr>
<td>Data and Analyses</td>
<td>22</td>
</tr>
<tr>
<td>Analysis 2.1. Comparison 2 Comparison among various psychosocial interventions, Outcome 1 12 months (point prevalence)</td>
<td>23</td>
</tr>
<tr>
<td>Analysis 2.2. Comparison 2 Comparison among various psychosocial interventions, Outcome 2 6 months (point prevalence)</td>
<td>23</td>
</tr>
<tr>
<td>Analysis 3.1. Comparison 3 Psychosocial and pharmacological interventions vs no intervention, Outcome 1 5 years (sustained abstinence): experimental 1 vs control</td>
<td>24</td>
</tr>
<tr>
<td>Analysis 3.2. Comparison 3 Psychosocial and pharmacological interventions vs no intervention, Outcome 2 5 years (sustained abstinence): experimental 2 vs control</td>
<td>24</td>
</tr>
<tr>
<td>Analysis 3.3. Comparison 3 Psychosocial and pharmacological interventions vs no intervention, Outcome 3 1 year (sustained abstinence) experimental 1 vs control</td>
<td>25</td>
</tr>
<tr>
<td>Analysis 3.4. Comparison 3 Psychosocial and pharmacological interventions vs no intervention, Outcome 4 1 year (sustained abstinence) experimental 2 vs control</td>
<td>25</td>
</tr>
<tr>
<td>Analysis 4.1. Comparison 4 Comparison among various combinations of psychosocial and pharmacological interventions, Outcome 1 6 months (continuous abstinence)</td>
<td>26</td>
</tr>
<tr>
<td>What’s New</td>
<td>26</td>
</tr>
<tr>
<td>History</td>
<td>26</td>
</tr>
<tr>
<td>Contributions of Authors</td>
<td>26</td>
</tr>
<tr>
<td>Declarations of Interest</td>
<td>26</td>
</tr>
<tr>
<td>Sources of Support</td>
<td>27</td>
</tr>
<tr>
<td>Index Terms</td>
<td>27</td>
</tr>
</tbody>
</table>
**ABSTRACT**

**Background**

Smoking cessation is the most important treatment for smokers with chronic obstructive pulmonary disease (COPD), but little is known about the effectiveness of different smoking cessation interventions for this particular group of patients.

**Objectives**

To determine the effectiveness of smoking cessation interventions in people with COPD.

**Search strategy**

Electronic searches were undertaken on MEDLINE (from 1966 to March 2002), EMBASE (from 1989 to March 2002) and Psyclit (from 1971 to March 2002), and CENTRAL (Issue 1, 2002). Searches were current as of October 2003.

**Selection criteria**

Randomised controlled trials in which smoking cessation was assessed in participants with confirmed COPD.

**Data collection and analysis**

Two authors extracted the data and performed the methodological quality assessment independently for each study, with disagreements resolved by consensus. High-quality was defined, based on pre-set criteria according to the DelphiList.

**Main results**

Five studies were included in this systematic review, two of which were of high-quality. The high-quality studies show the effectiveness of psychosocial interventions combined with pharmacological intervention compared to no treatment: psychosocial interventions combined with nicotine replacement therapy (NRT) and a bronchodilator versus no treatment at a 5 year follow-up (RD = 0.16, 95% CI 0.14 to 0.18), (RR = 4.0, 95% CI 3.25 to 4.93), psychosocial interventions combined with NRT and placebo versus no treatment at a 5 year follow-up (RD = 0.17, 95% CI 0.14 to 0.19), (RR = 4.19, 95% CI 3.41 to 5.15). Furthermore the results show the effectiveness of various combinations of psychosocial and pharmacological interventions at a 6 months follow-up (RD = 0.07, 95% CI 0.0 to 0.13), (RR = 1.74, 95% CI 1.01 to 3.0). Unfortunately, none of the included studies compared psychosocial interventions with no treatment. Therefore we found no evidence with regard to the effectiveness of these interventions. An update search in October 2003 did not identify any new studies for inclusion in the review.
Authors’ conclusions

Based on this systematic review, the authors found evidence that a combination of psychosocial interventions and pharmacological interventions is superior to no treatment or to psychosocial interventions alone. Furthermore we conclude that there is no clear or convincing evidence for the effectiveness of any psychosocial intervention for patients with COPD due to lack of a sufficient number of high-quality studies.

Plain Language Summary

Psychosocial interventions to help people with chronic bronchitis and emphysema to quit smoking.

Smoking cessation is the most important treatment for smokers with chronic bronchitis and emphysema. Smoking cessation interventions can be divided into psychosocial interventions (e.g. counselling, self-help materials, and behavioral therapy) and pharmacotherapy (e.g. nicotine replacement therapy, bupropion). Although a lot of research has been done on the effectiveness of interventions for “healthy” smokers, the effectiveness of smoking cessation interventions for smokers with chronic bronchitis and emphysema has so far gained far less attention. However, there is some evidence that combining psychosocial intervention with pharmacotherapy could be effective for this group of smokers trying to quit smoking. More research is needed to determine what kinds of interventions are most effective for which kind of patient.

Background

Chronic obstructive pulmonary disease (COPD) is a disease state characterised by airflow limitation that is not fully reversible (Pauwels 2001a). The airflow limitation is usually both progressive and associated with an abnormal inflammatory response of the lungs to noxious particles or gases (Pauwels 2001a). The diagnosis can be confirmed by spirometry.

Prevalence and morbidity data greatly underestimate the total burden of COPD because the disease is usually not diagnosed until it is clinically apparent and moderately advanced (Pauwels 2001a). Precise figures on prevalence are therefore surprisingly scanty, but it was estimated that in 1995 16.4 million people in the United States had COPD (ALA 1999). The estimated prevalence increased from 33.9 per 1000 patients in 1982 to 55.5 per 1000 patients in 1995 (ALA 1999). COPD is now the fourth leading cause of death in the United States, and it is the only common cause of death that is increasing in incidence (Barnes 2000). There has been an increase in the prevalence of and mortality from COPD, even in industrialized countries (ATS 1995). The World Health Organization (WHO) predicts that by 2020 COPD will have risen from its current ranking as the 12th most prevalent disease worldwide to the 5th, and from the 6th most common cause of death to the 3rd (Lopez 1998).

Cigarette smoking is by far the most important risk factor for COPD and the most significant way in which tobacco use contributes to the risk of COPD (Pauwels 2001a; Pauwels 2001b; Doll 1994). The forced expiratory volume in 1 second (FEV1) declines with normal aging (in non-smokers) at about 30 ml/year and this increases to an average of 45 ml/year in smokers (Fletcher 1976). Also, an increasing exposure to tobacco smoke will lead to a higher risk of developing COPD (Burrows 1979). The only other risk factor of comparable importance for the individual is homozygous alpha-antitrypsin (AAT) deficiency, but that heritable condition accounts for less than 1% of COPD cases (ATS 1995). Smokers have higher death rates as a result of chronic bronchitis and emphysema (ATS 1995). Furthermore, they have a higher prevalence of respiratory symptoms and lung function abnormalities, a greater COPD mortality rate than non-smokers, and a greater annual rate of decline in FEV1. These differences between cigarette smokers and non-smokers increase in direct proportion to the quantity of smoking (Pauwels 2001a; Pauwels 2001b; ATS 1995).

Smoking cessation is the single most effective and cost-effective way to reduce the risk of developing COPD. Furthermore, smoking cessation is the single most important way of affecting outcome in patients at all stages of COPD (Pauwels 2001a; Doll 1994; Traver 1979; Fletcher 1976). Smoking cessation is the only evidence-based treatment (as confirmed in the Lung Health Study (Anthonisen 1994)), which has been proven to slow down the de-
velopment of the disease by preventing further deterioration of the lung function. Following smoking cessation, the annual decline in FEV1 is usually reduced, sometimes to the level of non-smokers. Smoking cessation interventions can be divided into psychosocial interventions and pharmacological interventions. Although smoking cessation is seen as the most important preventive measure in patients with COPD, little is known about the effectiveness of different smoking cessation interventions directed at such patients.

OBJECTIVES

The overall objectives of this review are to evaluate the effectiveness of any psychosocial or pharmacological smoking cessation intervention or combinations of both for patients with COPD. We also want to determine what kind of psychosocial interventions are most effective. The last objective is to determine which pharmacological intervention is most effective.

Comparisons investigated:

1. Psychosocial intervention versus no intervention;
2. Comparison among various psychosocial interventions;
3. Psychosocial and pharmacological interventions versus no intervention;
4. Comparison among the various combinations of psychosocial and pharmacological interventions.

METHODS

Criteria for considering studies for this review

Types of studies

Randomised controlled trials with a minimum follow-up of six months and an inclusion criterion of clinical diagnosis of COPD, according to the ATS, BTS or GOLD criteria or confirmed by the treating physician. We chose a minimum follow-up of six months because this, together with the 12 months follow-up, is the "gold standard" for studies.

Types of participants

Participants with a diagnosis of COPD, according to the ATS, BTS or GOLD criteria or confirmed by the treating physician, who were smokers at the time of investigation, were included.

Types of interventions

Randomised controlled trials, in which the effectiveness of any psychosocial or pharmacological intervention or combinations of both was assessed as an aid to smoking cessation in patients with COPD, were included. Psychosocial interventions refer to intervention strategies that are designed to increase tobacco abstinence rates due to psychological or social support mechanisms. These interventions comprise such treatment strategies as counselling, self-help materials, and behavioural treatment (US DHHS 2000). Pharmacological interventions comprise nicotine replacement therapy (NRT) or non-nicotine pharmacotherapy. Currently, the following NRT delivery systems are available: nicotine chewing gum, nicotine inhaler, nicotine microtab, nicotine patch, and nicotine nasal spray. Bupropion and nortriptyline are the most used non-nicotine pharmacotherapy. Pharmacological intervention is often combined with a psychosocial intervention. Psychosocial interventions were evaluated by the following characteristics: formats of psychosocial intervention, types of counselling and behavioural therapy as part of the psychosocial intervention, and intensity of person-to-person clinical contact. The format of psychosocial intervention was categorized into (1) no contact, (2) self-help / self-administered (e.g., pamphlet, audiotape, videotape, mailed information, computer program), (3) individual counselling/contact, (4) group counselling/contact, (5) proactive telephone counselling/contact, and (6) number of types of formats (US DHHS 2000). The type of counselling and behavioural therapy was categorized into (1) no person-to-person intervention or minimal counselling, (2) general: problem solving / coping skills / relapse prevention / stress management approach, (3) negative effect / depression intervention, (4) extra-treatment social support intervention, (5) intratreatment social support intervention, (6) contingency contracting / instrumental contingencies, (7) rapid smoking, (8) other aversive smoking techniques, (9) cigarette fading / smoking reduction pre-quit, and (10) acupuncture (US DHHS 2000). The intensity of person-to-person clinical contact was categorized into (1) no person-to-person intervention, (2) minimal counselling (longest session < 3 minutes in duration), (3) low intensity counselling (longest session > 3 minutes and < 10 minutes in duration), (4) higher intensity counselling (longest session > 10 minutes), (5) total amount of contact time (the number of sessions multiplied by the session length), (6) number of person-to-person treatment sessions (US DHHS 2000).

Types of outcome measures

Randomised controlled trials that were considered were included if they used at least one of the following outcome measures: 1. Continuous abstinence measured at least 6 months after the start of the intervention. An outcome of continuous abstinence
is the percentage of former smokers who have not smoked at all since time of intervention (Velicer 1992).

2. Point prevalence of smoking cessation, measured at least 6 months after the start of the intervention. Point prevalence is the percentage of former smokers who were not smoking at a particular point in time (Velicer 1992). When it was not clear whether the given quit rate was point prevalence or continuous abstinence we defined the quit rate as point prevalence. Both validated abstinence based on biochemical markers and abstinence based on self-report via telephone and postal questionnaires were included. Continuous abstinence was used as the primary outcome measure. Point prevalence abstinence rates were considered as secondary outcome measures. In studies that used biochemically validated cessation rates, only those subjects meeting the criteria for biochemically confirmed abstinence were regarded as having stopped smoking.

3. Lung function measured by forced expiratory volume in 1 second (FEV1).

Search methods for identification of studies

All relevant trials meeting our inclusion criteria were identified by:

1. A computer aided search of MEDLINE (from 1966 to March 2002), EMBASE (from 1989 to March 2002) and Psyclit (from 1971 to March 2002) databases using the search strategy recommended by the Airways Group;

2. Screening references given in relevant reviews and identified randomised controlled trials (i.e. reference tracking);

3. Screening of the Cochrane controlled trials register, Issue 1, 2002;

Unpublished studies or abstracts were included if sufficient detail was available. Authors were contacted for further data if necessary.

The following Medical Subject Headings, MeSH subheadings and free text words were used in the literature search:

The terms were connected and the results were limited to studies reporting only on human subjects and randomised controlled trials. We had no limitations on language.

Data collection and analysis

STUDY SELECTION

Two reviewers (RVDM and EJW) independently selected the studies to be included in the systematic review, by applying selection criteria to the studies that were retrieved by the literature search. Consensus was used to resolve disagreements concerning selection and inclusion of studies and a third reviewer (RO) was consulted if disagreements persisted.

METHODOLOGICAL QUALITY ASSESSMENT

To assess the methodological quality of selected studies, the Delphi List (Verhagen 1998) was used (Table 1), consisting of internal validity, descriptive and statistical criteria. Two reviewers (RVDM and EJW) independently assessed the methodological quality of included studies. The items of the Delphi-list were scored as “yes”, “no” or “unclear”. A total score was computed by counting the numbers of “yes” scores on the items, and high quality was defined as fulfilling five (56%) or more of the validity items.

Table 1. The Delphi list (Verhagen 1998)

<table>
<thead>
<tr>
<th>Items</th>
<th>Answer-option</th>
</tr>
</thead>
<tbody>
<tr>
<td>1. Treatment allocation</td>
<td></td>
</tr>
<tr>
<td>a. Was a method of randomisation performed?</td>
<td>Yes / No / Don’t know</td>
</tr>
<tr>
<td>b. Was the treatment allocation concealed?</td>
<td>Yes / No / Don’t know</td>
</tr>
<tr>
<td>2. Were the groups similar at baseline regarding the most important prognostic indicators?</td>
<td>Yes / No / Don’t know</td>
</tr>
<tr>
<td>3. Were the eligibility criteria specified?</td>
<td>Yes / No / Don’t know</td>
</tr>
<tr>
<td>4. Was the outcome assessor blinded?</td>
<td>Yes / No / Don’t know</td>
</tr>
</tbody>
</table>
Table 1.  The Delphi list (Verhagen 1998)  (Continued)

<table>
<thead>
<tr>
<th>Question</th>
<th>Yes / No / Don't know</th>
</tr>
</thead>
<tbody>
<tr>
<td>5. Was the care provider blinded?</td>
<td>Yes / No / Don't know</td>
</tr>
<tr>
<td>6. Was the patient blinded?</td>
<td>Yes / No / Don't know</td>
</tr>
<tr>
<td>7. Were point estimates and measures of variability presented for the primary outcome measures?</td>
<td>Yes / No / Don't know</td>
</tr>
<tr>
<td>8. Did the analysis include an intention-to-treat analysis?</td>
<td>Yes / No / Don't know</td>
</tr>
</tbody>
</table>

We decided not to blind studies for authors, the institution or the journal because the reviewers who performed the quality assessment were familiar with the literature. A consensus method was used to resolve disagreements and a third reviewer (RO) was consulted if disagreements persisted. If the article did not contain enough information regarding the methodological criteria (i.e., if one or more criteria were scored “unclear”), the reviewers contacted the authors for additional information.

**DATA EXTRACTION**

Two reviewers (RVDM and EJW) independently extracted data from the studies using a standardized form. A consensus method was used to resolve disagreements and a third reviewer (RO) was consulted if disagreements persisted. The data-extraction form was pre-tested using two RCTs on smoking cessation but not in patients with COPD.

**DATA ANALYSIS**

Studies were heterogeneous with regard to the following areas: 1. Study population (early signs of COPD versus patients with COPD stage II FVE1/FVC < 70% and FEV1 35 - 49%) 2. Format of treatment (individual counselling versus telephone counselling combined with individual counselling and bupropion). 3. Reference treatments (no treatment versus individual counselling combined with self-help material). 4. Motivation to quit (different stages of motivation versus motivated). 5. Quality criteria (low quality versus high quality). 6. Outcomes (point prevalence at six months versus continuous abstinence at 12 months). 7. Outcome measurement (no biochemical validation versus biochemical validation). Therefore no meta-analysis was performed. Risk differences, relative risks, and 95% CI were calculated for every study.

**RESULTS**

**Description of studies**

See: Characteristics of included studies; Characteristics of excluded studies.

Three hundred and eighteen publications were identified in MEDLINE, EMBASE and Psyclit. The first selection was based on titles, keywords, and abstracts, and resulted in both reviewers including 12 studies. Another 17 studies were included through reference tracking. The final selection was based on the full papers (29 studies) and resulted in exclusion of 24 studies and inclusion of five studies (Tashkin 2001; Brandt 1997; Crowley 1995; Anthonisen 1994; Pederson 1991). The table characteristics of excluded studies summarizes the excluded studies and the reason for exclusion. The table characteristics of included studies summarizes the characteristics of the included studies. Two of these studies were reported in two publications (Brandt 1997; Kallan 1997) and 11 publications (Anthonisen 1994; Anthonisen 1997; Buist 1993 & 1997; Connett 1993a & 1993b; Kanner 1996 & 1999; Murray 1998 & 2000; O’Hara 1998).

An update search in October 2003 did not identify any studies for inclusion in the review. This review includes five studies, the characteristics of which are summarized in table: characteristics of included studies. Two studies compared different psychosocial interventions (Brandt 1997; Pederson 1991). One study compared psychosocial and pharmaceutical intervention with no intervention (Anthonisen 1994). Two studies compared various combinations of psychosocial and pharmacological interventions (Tashkin 2001; Crowley 1995).

**Risk of bias in included studies**

Table 2 shows the final results of the quality assessment. After consensus, six (13%) of the 45 quality assessments (five studies, nine criteria) were scored “unclear”. Three authors responded to a request and provided additional information on their studies. As
a result, three “unclear” scores were changed into negative.

Table 2. Quality Assessment Delphi-list

<table>
<thead>
<tr>
<th>Reference</th>
<th>1a / 1b</th>
<th>2</th>
<th>3</th>
<th>4</th>
<th>5</th>
<th>6</th>
<th>7</th>
<th>8</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>Anthonisen (1994)</td>
<td>+ / -</td>
<td>+</td>
<td>+</td>
<td>-</td>
<td>-</td>
<td>+</td>
<td>+</td>
<td>5</td>
<td></td>
</tr>
<tr>
<td>Crowley (1995)</td>
<td>+ / -</td>
<td>+</td>
<td>+</td>
<td>-</td>
<td>-</td>
<td>+</td>
<td>-</td>
<td>4</td>
<td></td>
</tr>
<tr>
<td>Tashkin (2001)</td>
<td>+ / +</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>9</td>
<td></td>
</tr>
</tbody>
</table>

“+” denotes yes, “-” denotes no and “?” denotes don’t know

According to the Delphi-list only two studies (40%) had five or more “yes” scores, which was our preset threshold for high quality (Tashkin 2001; Anthonisen 1994). The items regarding eligibility criteria (item 3) and point estimates and measures of variability (item 7) were met by 100% of the studies. The item regarding the most important prognostic indicators (item 2) were met by 80% of the studies (Tashkin 2001; Crowley 1995; Pederson 1991; Anthonisen 1994). The item regarding method of randomisation (item 1a) were met by 60% of the studies (Tashkin 2001; Crowley 1995; Anthonisen 1994). The patient, the care provider, and the outcome assessor were blinded in only one study (Tashkin 2001).

Effects of interventions

Table 3 summarizes the Risk Differences and the abstinence rates as described in the studies. Table 4 summarizes the Relative Risks and the abstinence rates as described in the studies. We also performed intention-to-treat analysis for the studies, but the results hardly changed.

Table 3. Abstinence rates as described in articles and risk differences (RD)

<table>
<thead>
<tr>
<th>Study</th>
<th>Intervention 6m n(%)</th>
<th>Control 6m n(%)</th>
<th>RD (95% CI) 6m</th>
<th>Intervention 1y n(%)</th>
<th>Control 1y n(%)</th>
<th>RD (95% CI) 1y</th>
<th>Intervention 5y n(%)</th>
<th>Control 5y n(%)</th>
<th>RD (95% CI) 5y</th>
</tr>
</thead>
</table>

Smoking cessation for chronic obstructive pulmonary disease (Review)
Table 3. Abstinence rates as described in articles and risk differences (RD)  

<table>
<thead>
<tr>
<th>Author</th>
<th>Year</th>
<th>Continuous Abstinence Rate</th>
<th>Point Prevalence Rate</th>
<th>Intervention</th>
<th>Control</th>
<th>Risk Difference</th>
</tr>
</thead>
<tbody>
<tr>
<td>Anthonisen</td>
<td>1994</td>
<td>680 (34.7)d e</td>
<td>177 (9.0)d e</td>
<td>0.26 (0.23 to 0.28)</td>
<td>408 (20.8)d e</td>
<td>102 (5.2)d e</td>
</tr>
<tr>
<td>Brandt</td>
<td>1997</td>
<td>674 (34.4)d f</td>
<td>177 (9.0)d f</td>
<td>0.25 (0.23 to 0.28)</td>
<td>427 (21.8)d e</td>
<td>102 (5.2)d e</td>
</tr>
<tr>
<td>Crowley</td>
<td>1995</td>
<td>8 (40.0)b</td>
<td>5 (20.0)b</td>
<td>0.20 (-0.07 to 0.47)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pederson</td>
<td>1991</td>
<td>5 (13.9)b c</td>
<td>5 (13.9)b c</td>
<td>0</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tashkin</td>
<td>2001</td>
<td>32 (15.7)a</td>
<td>18 (9.0)a</td>
<td>0.07 (0.00 to 0.13)</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

“a” denotes continuous abstinence, and “b” denotes point prevalence, and “c” denotes the intervention and two control groups in total, and “d” denotes sustained abstinence.

Copyright © 2009 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Table 3. Abstinence rates as described in articles and risk differences (RD) (Continued)

<table>
<thead>
<tr>
<th>Study</th>
<th>Intervention n(%) 6m</th>
<th>Control n(%) 6m</th>
<th>RR (95% CI)</th>
<th>Intervention n(%) 1y</th>
<th>Control n(%) 1y</th>
<th>RR (95% CI)</th>
<th>Intervention n(%) 5y</th>
<th>Control n(%) 5y</th>
<th>RR (95% CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Anthonisen</td>
<td>680 (34.7) de</td>
<td>177 (9.0) de</td>
<td>3.85 (3.30 to 4.48)</td>
<td>408 (20.8) de</td>
<td>102 (5.2) de</td>
<td>4.0 (3.25 to 4.93)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>(1994)</td>
<td>674 (34.4) df</td>
<td>177 (9.0) df</td>
<td>3.81 (3.27 to 4.44)</td>
<td>427 (21.8) df</td>
<td>102 (5.2) df</td>
<td>4.19 (3.41 to 5.15)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Brandt</td>
<td>8 (40.0) b</td>
<td>5 (20.0) b</td>
<td>2.0 (0.77 to 5.17)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>(1997)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Table 4. Abstinence rates as described in articles and relative risks (RR)

<table>
<thead>
<tr>
<th>Study</th>
<th>Intervention n(%) 6m</th>
<th>Control n(%) 6m</th>
<th>RR (95% CI)</th>
<th>Intervention n(%) 1y</th>
<th>Control n(%) 1y</th>
<th>RR (95% CI)</th>
<th>Intervention n(%) 5y</th>
<th>Control n(%) 5y</th>
<th>RR (95% CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Anthonisen</td>
<td>680 (34.7) de</td>
<td>177 (9.0) de</td>
<td>3.85 (3.30 to 4.48)</td>
<td>408 (20.8) de</td>
<td>102 (5.2) de</td>
<td>4.0 (3.25 to 4.93)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>(1994)</td>
<td>674 (34.4) df</td>
<td>177 (9.0) df</td>
<td>3.81 (3.27 to 4.44)</td>
<td>427 (21.8) df</td>
<td>102 (5.2) df</td>
<td>4.19 (3.41 to 5.15)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Brandt</td>
<td>8 (40.0) b</td>
<td>5 (20.0) b</td>
<td>2.0 (0.77 to 5.17)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>(1997)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Copyright © 2009 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Table 4. Abstinence rates as described in articles and relative risks (RR)

<table>
<thead>
<tr>
<th>Study (Year)</th>
<th>Continuous (a)</th>
<th>Point Prevalence (b)</th>
<th>RR (95% CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Crowley (1995)</td>
<td>5 (13.9)</td>
<td>5 (13.9)</td>
<td>(Continued)</td>
</tr>
<tr>
<td>Pederson (1991)</td>
<td>10 (33.3)</td>
<td>6 (21.4)</td>
<td>1.56 (0.65 to 3.72)</td>
</tr>
<tr>
<td>Tashkin (2001)</td>
<td>32 (15.7)</td>
<td>18 (9.0)</td>
<td>1.74 (1.01 to 3.0)</td>
</tr>
</tbody>
</table>

“a” denotes continuous abstinence, and “b” denotes point prevalence, and “c” denotes the intervention and two control groups in total, and “d” denotes sustained abstinence, and “e” denotes smoking cessation intervention and bronchodilator versus control group, and “f” denotes smoking cessation and placebo versus control group, and “g” denotes intention to treat analysis, and “6m” denotes 6 months follow-up, “1y” denotes for 1 year follow-up, and “5y” denotes for 5 years follow-up.

1. **Psychosocial intervention versus no intervention.**

No studies were found for the comparison of psychosocial intervention with no intervention.

2. **Comparison among different psychosocial interventions**

Two studies were identified that compared different psychosocial interventions (Brandt 1997; Pederson 1991). One of these studies compared individual counselling in combination with self-help in the experimental group with individual counselling in combination with self-help in the control group (Brandt 1997). The difference between the two treatment arms was that in the experimental group the lung disease was designated ‘smokers lung’ in information material and when the medical staff talked to the patients about their illness whereas in the control group the lung disease was called chronic bronchitis or emphysema. Intensity of person-to-person clinical contact, total amount of contact time, number of sessions, and type of counselling and behavioural therapy were not described. The point prevalence at month 12 was 40% (n=8) in the experimental group, versus 20% (n=5) in the control group. The risk difference (RD) was 0.2 (95% CI -0.07 to 0.47) and the relative risk (RR) was 2.0 (95% CI 0.77 to 5.17). The other study (Pederson 1991) compared individual counselling (higher intensity, average amount of time about 100 minutes, 3 - 8 sessions, and type not clear) and the use of a self-help cessation manual in the experimental group, with individual counselling (Intensity of person-to-person clinical contact, total amount of contact time, and type of counselling and behavioural therapy were not stated, 1 session) in the control group. The continuous abstinence at six months after admission was 33% (n=10) in the experimental group, versus 21% (n=6) in the control group (RD = 0.12, 95% CI -0.11 to 0.35), (RR = 1.56, 95% CI 0.65 to 3.72).

3. **Psychosocial and pharmacological interventions versus no intervention.**

One study compared two experimental interventions (experimental group 1 and experimental group 2) with the control group (group 3) (Anthonisen 1994). The participants in the experimental group 1 received individual counselling in combination with group counselling, pharmacotherapy (NRT) and a bronchodilator. The participants in the experimental group 2 also received individual counselling in combination with group counselling, pharmacotherapy (NRT) but a placebo instead of a bronchodilator. Receiving a bronchodilator or a placebo was the only difference between experimental group 1 and 2. The participants in the control group (group 3) received no intervention. The intensity of person-to-person clinical contact and total amount of contact time were not stated in both experimental groups. The individual counselling comprised one session and the group counselling comprised 12 sessions over 10 weeks. There was also a maintenance programme. The sustained abstinence at 1 year (intention-to-treat) was 34.7%
A study compared proactive telephone counselling combined with individual counselling and pharmacotherapy (bupropion) in the experimental group, with the same proactive telephone counselling combined with individual counselling and pharmacotherapy (group 3). These estimated changes all differed significantly (p<.005 for each comparison).

The estimated mean changes in post bronchodilator FEV1 during the first year of follow-up were: a 38.8 mL increase (SE, 4.3 mL) in experimental group 1; a 11.2 mL increase (SE, 4.3) in experimental group 2; and a 34.4 mL decrease (SE, 4.3 mL) in the control group (group 3). These estimated changes all differed significantly (p<.005 for each comparison).

Average decreases from baseline to the fifth year of follow-up were: experimental group 1, 184 mL; experimental group 2, 209 mL; and the control group (group 3), 267 mL (no standard deviations presented). All pair wise comparisons between groups were significant (p<.002).

4. Comparison among various combinations of psychosocial and pharmacological interventions.

Two studies were identified that compared various combinations of psychosocial and pharmacological interventions (Tashkin 2001; Crowley 1995). One study compared proactive telephone counselling combined with individual counselling and pharmacotherapy (bupropion) in the experimental group, with the same proactive telephone counselling combined with individual counselling and placebo in the control group (Tashkin 2001). The intensity of person-to-person clinical contact, total amount of contact time, and type of counselling and behavioural therapy were not described. There was 1 telephone counselling session 3 days after the target quit date and 9 individual counselling sessions in weeks 1 to 7, week 10, and week 12. The continuous abstinence during weeks 4 - 26 (intention-to-treat) was 15.7% (n=32) in the experimental group, versus 9.0% (n=18) in the control group (RD = 0.7, 95% CI 0.0 to 0.13), (RR = 1.74, 95% CI 1.01 to 3.0).

The second study included a comparison among different combinations of individual counselling combined with self-help and pharmacotherapy (Crowley 1995). All groups received the same pharmacotherapy (NRT) and self-help, but received different kinds of individual counselling. All groups received higher intensity counselling from the physician (total amount of time was 30 minutes, 1 session and type of counselling and behavioural therapy was not described). All groups also received 1 or 2 daily home visits for 85 days by a technician for measuring CO and self-report of smoking behaviour. Lottery tickets reinforced the experimental group for reduced CO. The first control group was not informed about their CO-values and received lottery tickets equal to participants earnings. Neither was the second control group informed about their CO-values and they received lottery tickets when they reported not having smoked since the last home-visit. Point prevalence at six months was 13.9% (n=5) for all groups in total. However, due to lack of clear presentation of the data it was not possible to calculate risk differences and relative risks.

DISCUSSION

This systematic review is the first one, as far as we know, which evaluates the effectiveness of any psychosocial or pharmacological smoking cessation intervention or combinations of both for patients with COPD. Therefore, it is not possible to compare our results with other systematic reviews, because their focus was not on patients with COPD. The majority of these reviews assessed the effectiveness of smoking cessation interventions in the general, non COPD, population. Lancaster (2000) and the US Department of Health and Human Services (2000) found evidence for the effectiveness of psychosocial interventions in the general population: according to Lancaster et al., advice from doctors, structured interventions from nurses, and individual and group counselling are effective interventions. Furthermore, generic self-help materials are no better than brief advice but more effective than doing nothing. The U.S. Department of Health and Human Services reports that treatments involving person-to-person contact through individual, group, or proactive telephone counselling are consistently effective in smoking cessation. Whether this holds true, if patients with COPD are included, is a question to be answered by future research.

We found a few studies aimed at a mixed population including patients with COPD. However, no separate clear analysis of the results regarding this sub-population was reported. To gain insight in the effectiveness of smoking cessation interventions it would be worthwhile to report sub-analysis for separate patient categories whenever possible.

Although the number of included studies was very low, there were still some methodological obstacles:

Firstly, in general, the quality of the included studies was not satisfactory. However, some of the internal validity criteria of the Delphi-list are very difficult to achieve for studies in this specific field, especially the items with regard to blinding. One of the studies (Tashkin 2001) scored nine out of nine items. The remaining four studies (Brandt 1997; Crowley 1995; Anthonisen 1994; Pederson 1991) scored five or less out of nine. The reason for this is that Tashkin et al. compared psychosocial intervention in combination...
with pharmacotherapy with the same psychosocial intervention in combination with placebo. The focus in the other studies was on psychosocial interventions. It is far easier to provide blinding of patients and care-providers for pharmacotherapy than for psychosocial interventions. Although we are aware that the criteria with regard to blinding of patients and care-providers are difficult to achieve for psychosocial interventions they might still have introduced a bias. Therefore, they were not deleted from the quality assessment. However, in most studies blinding of outcome assessment is possible. In order to minimize bias as much as possible, it is of paramount importance to blind the outcome assessment. Redefining criteria to make them more suitable for psychosocial interventions should also be considered. More specifically, if blinding of patients is not feasible, this criterion could be scored positive, if treatment credibility is adequately evaluated and treatment was equally credible and acceptable to patients (Van Tulder 2001).

Secondly, in performing this review we observed much heterogeneity in the studies making it difficult to compare the results of individual studies. This especially concerns the type of included patients, the outcome measurements, and the timing of measurements.

First of all, we included studies that selected patients with a diagnosis of COPD, according to the ATS, BTS or GOLD criteria or where COPD was confirmed by the treating physician. Nevertheless, in some of the studies the stage of severity of COPD remained unclear. In order to determine what kind of patients benefit most from which kind of treatment, more detailed descriptions of the diagnosis (in-exclusion criteria) are called for.

Moreover, the outcome measurements used in the studies also hampered the comparison of the studies. Some studies use point prevalence as the outcome measure while other studies use continuous abstinence; and some use both. Unfortunately, sometimes it was not at all clear what kind of outcome measure had been used. For example, in one study the self-reported smoking habits were obtained by telephone interviews one year after discharge (Brandt 1995). From their description of how the outcome assessment was performed, it could not be determined whether point prevalence's or continuous abstinence was used.

Furthermore, the timing of measurement used in the studies differed considerably. Some studies measure the point prevalence at 6 months (Tashkin 2001; Crowley 1995), others measure the point prevalence at 1 year (Brandt 1997). Moreover, sometimes the timing is unclear. There are also differences between the studies at baseline. Some studies count the start-point as the beginning of the intervention. Tashkin et al. defined point prevalence at 6 months as 6 months after start of the intervention, while for Crowley et al. the exact start-point was not clear. The heterogeneity with regard to the outcome measurement and the timing of measurement also concerns previous reviews of smoking cessation interventions in the general healthy population. Obviously, it is still not clear what kind of outcome measurement and timing of measurement is most valid. According to Velicer et al. the use of a combination of outcome measurements (point prevalence abstinence, continuous abstinence, and prolonged abstinence) is often most appropriate in studies assessing the effects of a smoking cessation intervention. The major advantage of point prevalence is that it permits inclusion of a wide range of former smokers reflecting the dynamic nature of smoking cessation. A major advantage of prolonged and continuous abstinence rates is better assessment of the long-term health effects of cessation and the maintenance effect of the intervention. In the guideline of the U.S. Department of Health and Human Services (US DHHS 2000) the point prevalence abstinence, rather than continuous abstinence was used as the chief outcome variable. One of the reasons for preferring point prevalence above continuous abstinence data is that the latter underestimates the percentage of individuals who are abstinent at particular follow up time points. They might, therefore, suggest that the likelihood of cessation is lower than it actually is. Moreover, most relapses occur early in a quit attempt, and then persist. A point prevalence measure taken at 5 months would certainly capture the majority of those relapse events. To make comparisons of studies more worthwhile, consensus about the outcome measurement would be helpful. Therefore, we recommend the use of both continuous abstinence and point prevalence abstinence, with continuous abstinence as the primary outcome measure.

For the timing of measurement, two time points are particularly important: the baseline and the long-term follow-up. The baseline can be measured at the start of the intervention, at the quit-date or after the intervention. As long as the timing of the baseline assessment is accurately described, we have no particular preference for the way in which it is measured. The ‘gold standard’ for the long-term follow-up is 6 or 12 months (Hatsukami 1999). We recommend the use of both, because that allows an easier comparison of studies.

Furthermore the lung function was taken in account as a secondary outcome measurement because one of the primary aims for smoking cessation in patients with COPD is to slow the rate of decline in FEV1. But only one study of the included ones measured the differences in lung function (Anthonisen 1994). The results of this study show that the smaller declines in both smoking intervention groups, as compared to the control group, occurred mainly during the first year. For future research it would be interesting to take the lung function as a secondary outcome measurement.

Another difficulty in performing this review was the unclear description in most of the studies (e.g. intensity of person-to-person clinical contact, total amount of contact time within person-to-person clinical contact, and types of counselling and behavioural therapies were missing) The U.S. Department of Health and Human Services (2000) describes smoking cessation interventions for the general population, for example, in the following characteristics: formats of psychosocial intervention, types of counselling
and behavioural therapy, and intensity of person-to-person clinical contact. We think that this kind of description gives detailed information of the intervention. We recommend that interventions for smoking cessation for patients with COPD be described in the same terms and is necessary for making detailed recommendations for implementation in daily practice.

International guidelines for COPD (BTS, ATS, GOLD) recommend smoking cessation interventions for smokers with COPD that are similar to the interventions for healthy smokers. The reason for this is that there is not much evidence with regard to smoking cessation interventions that are specifically developed for smokers with COPD. But the question remains whether smokers with COPD are comparable to healthy smokers concerning determinants of smoking and determinants of smoking cessation interventions. If such is the case, interventions need to be tailored to their specific characteristics. Studies analysing the determinants of smokers with COPD, or assessing differences with those of the general healthy population are scarce (Jimenez-Ruiz 2001). Some authors indicate that smokers with COPD have a greater degree of physical nicotine dependence (Sach 1981; Sachs 1984). Jimenez-Ruiz (2001) shows that smokers with COPD have higher tobacco consumption, higher dependence on nicotine, and higher concentrations of CO in exhaled air, which suggests a different pattern of cigarette smoking. Cases of COPD among smokers predominate in men and in individuals with lower educational levels. Walters and Coleman (2002) describe a difference in attitudes and motivation to stop smoking in patients either or not attributing their respiratory symptoms to smoking. So did Clark (1999). Furthermore, patients with COPD have repeatedly been characterised as a population of chronically ill patients with a higher than normal prevalence of psychiatric disorders such as depression (Dudley 1980; Isoaho 1995). It is known that for smokers with depression or a history of depression it is far more difficult to quit smoking. Both are associated with failure to quit smoking and relapse.

Authors’ conclusions

Implications for practice

Based on two studies the authors found evidence that a combination of psychosocial interventions and pharmacological interventions is superior to no treatment or to psychosocial interventions alone. Furthermore we conclude that there is no absolute or convincing evidence for the effectiveness of any psychosocial intervention for patients with COPD due to lack of a sufficient number of high-quality studies.

Implications for research

In future research, it should be assessed whether the needs of patients with COPD are truly different than the needs of healthy smokers. If so future randomised controlled trials should investigate if tailoring interventions to those needs improves quit rates in patients with COPD.

Acknowledgements

We would like to thank Steve Milan, Toby Lasserson, and Karen Blackhall for her help with the search strategy. We also would like to thank John White for his editorial input, Chris Cates for checking over statistical questions, and Paul Jones. Furthermore, we would like to thank Nick Anthonisen, Linda Pederson, Thomas Crowley who responded to our enquiries. Finally, we would like to thank Marc Willemsen, Marcus Huibers, Geert Schattenberg and Clive Lawrence for their input.

References to studies included in this review

Anthonisen 1994 [published data only]


References to studies excluded from this review

Ames 1985 [published data only]

BTS 1983 [published data only]

BTS 1990a [published data only]

BTS 1990b [published data only]
Loss 1979 (published data only)


Paolietti 1993 (published data only)


Rose 1978 (published data only)


Sach 1988 (published data only)


Soulier 1985 (published data only)


Tonnesen 1988 (published data only)


Tonnesen 1996 (published data only)


Additional references

ALA 1999


ATS 1995


Barnes 2000


Burrows 1979


Clark 1999


Doll 1994


Dudley 1980


Fletcher 1976


Hatsukami 1999


Isahao 1995


Jimenez-Ruiz 2001a


Lancaster 2000


Lopez 1998


Pauwels 2001a


Pauwels 2001b


Sach 1981

Sachs 1984

Traver 1979

US DHHS 2000

Van Tulder 2001

Velicer 1992

Verhagen 1998

Walters 2002

* Indicates the major publication for the study
## Characteristics of Studies

### Characteristics of included studies [ordered by study ID]

#### Anthonisen 1994

| Methods | Setting: 10 clinical centers, USA and Canada.  
Recruitment: Methods of recruitment were classified in 5 strategies: worksites, public sites, mail/phone, media and other. Study participants were essentially healthy individuals recruited from the general population.  
Randomisation: Computer generated schedules, separately for each clinic. Blocks of random.  
Blinding: No.  
Drop-outs: Reasons described poorly.  
Intention-to-treat: Yes. |
|---|---|
| Participants | Participants: current smokers with spirometric signs of early COPD (FEV1/FVC < 70% and 55% < FEV1 < 90%),  
31 cig/day.  
Age: M:48.5 (R 35-60).  
Male: 62.9%.  
Physician confirmed: 7.2% asthma, 29.9% bronchitis, 3.1% emphysema.  
Motivation: Motivated to quit smoking. |
Format: Individual counselling and group counselling.  
Intensity: ?  
Time: ?  
Sessions: 1x physician before quit date and 12 x groups sessions over 10 weeks.  
Type: ? (principles of cognitive and social learning theory?).  
Pharmacotherapy: NRT (gum, supplied to participants who believed that it might help with their nicotine dependence, dose and duration not stated).  
Bronchodilator: ipratropium bromide 3 times daily (two puffs per time).  
2. Experimental 2 (n=1962):  
Same intervention as experimental 1, but instead of ipratropium they receive placebo.  
Follow-up on intervention for experimental group 1 and 2:  
a. Participants who quit entered a maintenance program, total not stated. (preventing relapse by teaching coping skills for problems such as stress and weight gain.  
b. Participants who relapsed were individually treated.  
Format: No contact.  
Type: No person-to-person intervention.  
Therapists: Physician and health educator. |
| Outcomes | Abstinence: Sustained abstinence at 1 and 5 year follow-up.  
Validation: Expired air CO and salivary cotinine. |
| Notes | Sustained quit rates denote individuals who had stopped smoking at the time of the initial cessation program and maintained this status at subsequent annual visits (1-5), also validated by cotinine or CO measurements; participants who did not attend a given annual visit were counted as smokers at that visit. |
| Methods | Setting: General medical ward (Hospital), Denmark.  
Recruitment: The patients with COPD were recruited from the medical department, without regard for their opinion about smoking cessation.  
Randomisation: Method not stated.  
Blinding: No.  
Drop-outs: Reasons were not completely described.  
Intention-to-treat: No. |
|---|---|
| Participants | Participants: Smoking patients with COPD admitted to a general medical ward.  
Criteria for COPD are described as "intermittent or chronic dyspnoea, coughing, changing grades of bronchio-obstruction and/or secretion-problems.  
Age: M 66 (r:38-88).  
Male: 52%.  
Motivation: Unknown. |
Format: Individual counselling and Self-help (The lung disease was designated 'smoker's lung' in information material and when the medical staff talked to the patients about their illness).  
Intensity: ?  
Time: ?  
Nsession: ?  
Type: ?  
Pharmacotherapy: No.  
2. Control (n=31): Psychosocial.  
Format: Individual counselling and Self-help (Illness called chronic bronchitis or emphysema).  
Intensity: ?  
Time: ?  
Nsession: ?  
Type: ?  
Pharmacotherapy: No.  
Therapists: medical staff |
| Outcomes | Abstinence: Point prevalence at month 12.  
Validation: Expired air CO. |
| Notes | A larger sample size was originally planned for this study but after 2 years the recruitment had been stopped because patients began spontaneously to call their illness smoker's lung and a true control group could not be obtained. Self-reports of smoking habits were obtained by telephone interviews at 1 year after discharge: Point prevalence or continuous abstinence? |
### Methods

Setting: Home visits, USA.
Recruitment: Screening of patients presenting to a general medical clinic and screening of all known COPD-patients in an outpatient pulmonary clinic.
Randomisation: Block randomisation, pre-stratification on sex and FEV1.
Blinding: No.
Drop-outs: Reasons not completely described.
Intention-to-treat: No.

### Participants

Participants: Quite-ill current smoking COPD patients (FEV1/FVC < 70%).
Age: M: 61.4.
Male: 75.7%.
Motivation: Different stages of motivation.

### Interventions

1. Experimental (n=18): Psychosocial and pharmacotherapy.
   Format: Individual contact.
   Intensity: 10 minutes (low-intensity).
   Time: 1 or 2 daily home visits on days 1-85.
   Type: Contingency contracting? (contingent reinforcement (lottery tickets) for reduced breath CO2.
   2. Control 1 (n=15): Psychosocial and pharmacotherapy.
   Format: Individual contact.
   Intensity: 10 minutes (low-intensity).
   Time: 1 or 2 daily home visits on days 1-85.
   Type: ? (non-contingent payment (lottery tickets) equal to pair-mates earnings. These participants were not informed about their CO-values.
   3. Control 2 (n=16): Psychosocial and pharmacotherapy.
   Format: Individual contact.
   Intensity: 10 minutes (low-intensity).
   Time: 1 or 2 daily home visits on days 1-85.
   Type: Contingency contracting? (Contingent reinforcement (lottery tickets) of self-report of no smoking since previous home visit. These participants were not informed of their CO-values).
   All groups received
   Intensity: Higher intensity counselling.
   Time: 30 minutes.
   Session: 1.
   Type: ?
   Pharmacotherapy: NRT (gum, 2 mg / piece, up to 30 pieces/day, days 11-75).
   Therapists: Physician for counselling and technician for home visits.

### Outcomes

Abstinence: Point prevalence at 6 months.
Validation: Expired air CO.

### Notes

Point prevalence of abstinence at month 6 was defined as no smoking on the day of follow-up and CO < 10.
Point prevalence of abstinence at month 6 was assessed only for the participants who completed the 6-month follow-up and was not specified for the three groups.
**Pederson 1991**

| Methods | Setting: Chest unit of a 600-bed teaching hospital, Canada.  
|         | Recruitment: Cigarette smoking patients with previously diagnosed COPD admitted to a Chest Unit.  
|         | Randomisation: Method not stated  
|         | Blinding: No.  
|         | Drop-outs: Reasons were stated.  
|         | Intention-to-treat: No. |

| Participants | Participants: Current smokers with COPD admitted to a hospital (Chest Unit). 43% had chronic bronchitis and 57% emphysema according to ACCP-ATS criteria.  
|              | Age: M: 53.4 (SD 13.7).  
|              | Male: 68.9%.  
|              | Motivation: Unknown.  
|              | 93% > 10 cig/day. |

| Interventions | 1. Experimental (n=37): Psychosocial. Format: Individual counselling (advice to quit smoking by their physician prior to admission follow-up intervention by trained assistant) and self-help (cessation manual).  
|               | Intensity: Higher intensity counselling (15-20 minutes).  
|               | Time: (3 - 8) * (15 - 20 minutes).  
|               | Nsession: 3 - 8.  
|               | Type: ? (Support and encouragement).  
|               | Pharmacotherapy: No.  
|               | 2. Control (n=37): Psychosocial.  
|               | Format: Individual counselling (advice to quit smoking by their physician prior to admission).  
|               | Intensity: ?  
|               | Time: ?  
|               | Nsession: 1.  
|               | Type: ?  
|               | Pharmacotherapy: No.  
|               | Therapists: Physician and trained assistant. |

| Outcomes | Abstinence: Continuous abstinence at 6 months after admission.  
|          | Validation: COHb analysis from blood samples drawn at 6 months. |

| Notes | COHb analysis from blood samples drawn from a random sample of 20 participants from those who could be examined.  
|       | Smoking was not permitted in the chest unit. |

**Tashkin 2001**

| Methods | Setting: 11 clinical centres, USA.  
|         | Recruitment: Print and radio advertisements.  
|         | Randomisation: Block randomisation (code provided by Glaxo Wellcome), using block sizes of 4, stratified by centre.  
|         | Blinding: Patient and provider.  
|         | Drop-outs: Reasons were stated.  
|         | Intention-to-treat analysis with data of patients who took at least one dose of study medication. |

| Participants | Participants: COPD patients stage I (FVE1/FVC < 70% and FEV1 > 50%) or II (FVE1/FVC < 70% and FEV1 35 -49%) (ATS-criteria), and had smoked 15 cigarettes or more per day for the previous year, and had not stopped smoking for more than 3 months during that year. |
Age: M 53.9 (SD 9.3).
Male: 55%.
Motivation: Motivated to quit smoking.

Interventions
1. Experimental (n=206) Psychosocial and pharmacotherapy.
   Pharmacotherapy: Bupropion SR 150 mg once daily for days 1-3, 150 mg twice daily on days 4-84.
2. Control (n=205): Psychosocial and placebo.
   Pharmacotherapy: Placebo.
Both groups received
Format: Proactive telephone counselling and individual counselling.
Intensity: ? (brief individual counselling).
Time: ?
N session: 10: 1 telephone counselling 3 days after the target date and 9 individual counselling, at weeks 1-7, 10, 12.
Type: ?
Therapists: Trained counsellor (generally a nurse or other health professional).

Outcomes
Abstinence: Continuous abstinence during weeks 4-26 and Point prevalence of abstinence at week 26.
Validation: Expired air CO.

Notes
Continuous abstinence for weeks 4 - 26 was defined by participants being continuously abstinent during weeks 4-12, having a diary cigarette count of zero during weeks 13-26, and having exhaled CO values of 10 ppm or less at week 26. Point prevalence of abstinence at week 26 was defined as smoking abstinence during the previous 7 days.

“M” = mean, “SD” = standard deviation, and “r” = range.
“Format” denotes formats of psychosocial intervention, and “Type” denotes types of counselling and behavioural therapies as part of psychosocial intervention.
“Intensity” denotes intensity of person-to-person clinical contact, and “Time” denotes total amount of contact time within person-to-person clinical contact, and “n sessions” denotes number of person-to-person treatment sessions.

Characteristics of excluded studies [ordered by study ID]

<table>
<thead>
<tr>
<th>Study</th>
<th>Reason for Exclusion</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ames 1985</td>
<td>COPD was no inclusion, no randomisation and no control group</td>
</tr>
<tr>
<td>BTS 1983</td>
<td>COPD was no inclusion criterion</td>
</tr>
<tr>
<td>BTS 1990a</td>
<td>COPD was no inclusion criterion</td>
</tr>
<tr>
<td>BTS 1990b</td>
<td>COPD was no inclusion criterion</td>
</tr>
<tr>
<td>Buist 1976</td>
<td>COPD was no inclusion criterion, no randomisation, no control and no smoking cessation trial</td>
</tr>
<tr>
<td>Camilli 1987</td>
<td>COPD was no inclusion criterion, no randomisation, no control group and no smoking cessation trial</td>
</tr>
<tr>
<td>Reference</td>
<td>Inclusion Criteria</td>
</tr>
<tr>
<td>--------------</td>
<td>-----------------------------------------------------------------------------------</td>
</tr>
<tr>
<td>Cheng 1997</td>
<td>No smoking cessation trial</td>
</tr>
<tr>
<td>Daughton 1980</td>
<td>No randomisation, no control group and no smoking cessation trial</td>
</tr>
<tr>
<td>Davis 1984</td>
<td>COPD was no inclusion criterion</td>
</tr>
<tr>
<td>Glover 1997</td>
<td>No randomisation and no control group</td>
</tr>
<tr>
<td>Gourlay 1996</td>
<td>COPD was no inclusion criterion, no randomisation, no control group and no smoking cessation trial</td>
</tr>
<tr>
<td>Hall 1983</td>
<td>COPD was no inclusion criterion</td>
</tr>
<tr>
<td>Hall 1984</td>
<td>COPD was no inclusion criterion, no randomisation, no control group and no smoking cessation trial</td>
</tr>
<tr>
<td>Humerfelt 1998</td>
<td>COPD was no inclusion criterion</td>
</tr>
<tr>
<td>Lewis 1998</td>
<td>COPD was no inclusion criterion</td>
</tr>
<tr>
<td>Li 1984</td>
<td>COPD was no inclusion criterion</td>
</tr>
<tr>
<td>Loss 1979</td>
<td>COPD was no inclusion criterion, no randomisation, no control group and no smoking cessation trial</td>
</tr>
<tr>
<td>Paoletti 1993</td>
<td>No smoking cessation trial (a study protocol)</td>
</tr>
<tr>
<td>Rose 1978</td>
<td>COPD was no inclusion criterion</td>
</tr>
<tr>
<td>Sachs 1988</td>
<td>No randomisation and no control group</td>
</tr>
<tr>
<td>Sirota 1985</td>
<td>COPD was no inclusion criterion, no randomisation, no control group</td>
</tr>
<tr>
<td>Soulier 1999</td>
<td>COPD was no inclusion criterion, no randomisation, no control group</td>
</tr>
<tr>
<td>Tonnesen 1988</td>
<td>COPD was no inclusion criterion</td>
</tr>
<tr>
<td>Tonnesen 1996</td>
<td>COPD was no inclusion criterion</td>
</tr>
</tbody>
</table>
### Comparison 2. Comparison among various psychosocial interventions

<table>
<thead>
<tr>
<th>Outcome or subgroup title</th>
<th>No. of studies</th>
<th>No. of participants</th>
<th>Statistical method</th>
<th>Effect size</th>
</tr>
</thead>
<tbody>
<tr>
<td>1 12 months (point prevalence)</td>
<td>1</td>
<td></td>
<td>Risk Difference (M-H, Fixed, 95% CI)</td>
<td>Totals not selected</td>
</tr>
<tr>
<td>2 6 months (point prevalence)</td>
<td>1</td>
<td></td>
<td>Risk Difference (M-H, Fixed, 95% CI)</td>
<td>Totals not selected</td>
</tr>
</tbody>
</table>

### Comparison 3. Psychosocial and pharmacological interventions vs no intervention

<table>
<thead>
<tr>
<th>Outcome or subgroup title</th>
<th>No. of studies</th>
<th>No. of participants</th>
<th>Statistical method</th>
<th>Effect size</th>
</tr>
</thead>
<tbody>
<tr>
<td>1 5 years (sustained abstinence): experimental 1 vs control</td>
<td>1</td>
<td></td>
<td>Risk Difference (M-H, Fixed, 95% CI)</td>
<td>Totals not selected</td>
</tr>
<tr>
<td>2 5 years (sustained abstinence): experimental 2 vs control</td>
<td>1</td>
<td></td>
<td>Risk Difference (M-H, Fixed, 95% CI)</td>
<td>Totals not selected</td>
</tr>
<tr>
<td>3 1 year (sustained abstinence): experimental 1 vs control</td>
<td>1</td>
<td></td>
<td>Risk Difference (M-H, Fixed, 95% CI)</td>
<td>Totals not selected</td>
</tr>
<tr>
<td>4 1 year (sustained abstinence): experimental 2 vs control</td>
<td>1</td>
<td></td>
<td>Risk Difference (M-H, Fixed, 95% CI)</td>
<td>Totals not selected</td>
</tr>
</tbody>
</table>

### Comparison 4. Comparison among various combinations of psychosocial and pharmacological interventions

<table>
<thead>
<tr>
<th>Outcome or subgroup title</th>
<th>No. of studies</th>
<th>No. of participants</th>
<th>Statistical method</th>
<th>Effect size</th>
</tr>
</thead>
<tbody>
<tr>
<td>1 6 months (continuous abstinence)</td>
<td>1</td>
<td></td>
<td>Risk Difference (M-H, Fixed, 95% CI)</td>
<td>Totals not selected</td>
</tr>
<tr>
<td>2 6 months (point prevalence)</td>
<td>0</td>
<td></td>
<td>Risk Difference (M-H, Fixed, 95% CI)</td>
<td>Totals not selected</td>
</tr>
</tbody>
</table>
Analysis 2.1. Comparison 2 Comparison among various psychosocial interventions, Outcome 1 12 months (point prevalence).

Review: Smoking cessation for chronic obstructive pulmonary disease

Comparison: 2 Comparison among various psychosocial interventions

Outcome: 1 12 months (point prevalence)

<table>
<thead>
<tr>
<th>Study or subgroup</th>
<th>Treatment</th>
<th>Control</th>
<th>Risk Difference</th>
<th>Risk Difference</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>n/N</td>
<td>n/N</td>
<td>M-H,Fixed,95% CI</td>
<td>M-H,Fixed,95% CI</td>
</tr>
<tr>
<td>Brandt 1997</td>
<td>8/20</td>
<td>5/25</td>
<td>0.20 [-0.07, 0.47]</td>
<td></td>
</tr>
</tbody>
</table>

-1 -0.5 0 0.5 1
Favours control Favours treatment

Analysis 2.2. Comparison 2 Comparison among various psychosocial interventions, Outcome 2 6 months (point prevalence).

Review: Smoking cessation for chronic obstructive pulmonary disease

Comparison: 2 Comparison among various psychosocial interventions

Outcome: 2 6 months (point prevalence)

<table>
<thead>
<tr>
<th>Study or subgroup</th>
<th>Treatment</th>
<th>Control</th>
<th>Risk Difference</th>
<th>Risk Difference</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>n/N</td>
<td>n/N</td>
<td>M-H,Fixed,95% CI</td>
<td>M-H,Fixed,95% CI</td>
</tr>
<tr>
<td>Pederson 1991</td>
<td>10/30</td>
<td>6/28</td>
<td>0.12 [-0.11, 0.35]</td>
<td></td>
</tr>
</tbody>
</table>

-1 -0.5 0 0.5 1
Favours control Favours treatment
Analysis 3.1. Comparison 3 Psychosocial and pharmacological interventions vs no intervention, Outcome 1
5 years (sustained abstinence): experimental 1 vs control.

Review: Smoking cessation for chronic obstructive pulmonary disease

Comparison: 3 Psychosocial and pharmacological interventions vs no intervention

Outcome: 1 5 years (sustained abstinence): experimental 1 vs control

<table>
<thead>
<tr>
<th>Study or subgroup</th>
<th>Treatment</th>
<th>Control</th>
<th>Risk Difference</th>
<th>Risk Difference</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>n/N</td>
<td>n/N</td>
<td>M-H,Fixed,95% CI</td>
<td>M-H,Fixed,95% CI</td>
</tr>
<tr>
<td>Anthonisen 1994</td>
<td>408/1961</td>
<td>102/1964</td>
<td>*</td>
<td>0.16 [ 0.14, 0.18 ]</td>
</tr>
</tbody>
</table>

Favours control  Favours treatment

Analysis 3.2. Comparison 3 Psychosocial and pharmacological interventions vs no intervention, Outcome 2
5 years (sustained abstinence): experimental 2 vs control.

Review: Smoking cessation for chronic obstructive pulmonary disease

Comparison: 3 Psychosocial and pharmacological interventions vs no intervention

Outcome: 2 5 years (sustained abstinence): experimental 2 vs control

<table>
<thead>
<tr>
<th>Study or subgroup</th>
<th>Treatment</th>
<th>Control</th>
<th>Risk Difference</th>
<th>Risk Difference</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>n/N</td>
<td>n/N</td>
<td>M-H,Fixed,95% CI</td>
<td>M-H,Fixed,95% CI</td>
</tr>
<tr>
<td>Anthonisen 1994</td>
<td>427/1962</td>
<td>102/1964</td>
<td>*</td>
<td>0.17 [ 0.14, 0.19 ]</td>
</tr>
</tbody>
</table>

Favours control  Favours treatment
### Analysis 3.3. Comparison 3 Psychosocial and pharmacological interventions vs no intervention, Outcome 3 1 year (sustained abstinence) experimental 1 vs control.

**Review:** Smoking cessation for chronic obstructive pulmonary disease  
**Comparison:** 3 Psychosocial and pharmacological interventions vs no intervention  
**Outcome:** 3 1 year (sustained abstinence) experimental 1 vs control

<table>
<thead>
<tr>
<th>Study or subgroup</th>
<th>Treatment n/N</th>
<th>Control n/N</th>
<th>Risk Difference M-H,Fixed 95% CI</th>
<th>Risk Difference M-H,Fixed 95% CI</th>
</tr>
</thead>
<tbody>
<tr>
<td>Anthonisen 1994</td>
<td>680/1961</td>
<td>177/1964</td>
<td>0.26 [0.23, 0.28]</td>
<td></td>
</tr>
</tbody>
</table>

-1 -0.5 0 0.5 1  
Favours control Favours treatment

### Analysis 3.4. Comparison 3 Psychosocial and pharmacological interventions vs no intervention, Outcome 4 1 year (sustained abstinence) experimental 2 vs control.

**Review:** Smoking cessation for chronic obstructive pulmonary disease  
**Comparison:** 3 Psychosocial and pharmacological interventions vs no intervention  
**Outcome:** 4 1 year (sustained abstinence) experimental 2 vs control

<table>
<thead>
<tr>
<th>Study or subgroup</th>
<th>Treatment n/N</th>
<th>Control n/N</th>
<th>Risk Difference M-H,Fixed 95% CI</th>
<th>Risk Difference M-H,Fixed 95% CI</th>
</tr>
</thead>
<tbody>
<tr>
<td>Anthonisen 1994</td>
<td>674/1962</td>
<td>177/1964</td>
<td>0.25 [0.23, 0.28]</td>
<td></td>
</tr>
</tbody>
</table>

-1 -0.5 0 0.5 1  
Favours control Favours treatment
**Analysis 4.1.** Comparison 4 Comparison among various combinations of psychosocial and pharmacological interventions, Outcome 1 6 months (continuous abstinence).

Review: Smoking cessation for chronic obstructive pulmonary disease

Comparison: 4 Comparison among various combinations of psychosocial and pharmacological interventions

Outcome: 1 6 months (continuous abstinence)

<table>
<thead>
<tr>
<th>Study or subgroup</th>
<th>Treatment</th>
<th>Control</th>
<th>Risk Difference</th>
<th>Risk Difference</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>n/N</td>
<td>n/N</td>
<td>M-H,Fixed,95% CI</td>
<td>M-H,Fixed,95% CI</td>
</tr>
<tr>
<td>Tashkin 2001</td>
<td>32/204</td>
<td>18/200</td>
<td>0.07 [ 0.00, 0.13 ]</td>
<td></td>
</tr>
</tbody>
</table>

**WHAT'S NEW**

Last assessed as up-to-date: 30 September 2003.

29 August 2008 Amended Converted to new review format.

**HISTORY**

Protocol first published: Issue 1, 2001

Review first published: Issue 2, 2003

4 September 2000 New citation required and conclusions have changed Substantive amendment

**CONTRIBUTIONS OF AUTHORS**

RM van der Meer (RVDM) and EJ Wagena (EJW) identified and selected all studies. Both reviewers also assessed the methodological quality of studies and performed the data extraction. RM van der Meer, EJ Wagena and RWJG Ostelo (RO) conducted the data analysis. RWJG Ostelo served as ‘third reviewer’ and was consulted in case of persisting disagreements with regard to the quality assessment and/or data extraction. JE Jacobs and CP van Schayck were involved in final decisions regarding in- and exclusion of studies, and with regard to judgements about results and conclusions. All authors were involved in writing the review protocol and the final review.
DECLARATIONS OF INTEREST

Annelies Jacobs is coordinator of a project, which is partly financed by GlaxoSmithKline. Her involvement does not seem to be a source of conflict of interest because scientific autonomy is guaranteed.

SOURCES OF SUPPORT

Internal sources

- Research Institute ExTra, Netherlands.

External sources

- Dutch Astma Foundation and Zorgonderzoek Nederland (ZON), Netherlands.
- Garfield Weston Foundation, UK.

INDEX TERMS

Medical Subject Headings (MeSH)

*Smoking Cessation; Behavior Therapy; Combined Modality Therapy; Counseling; Pulmonary Disease, Chronic Obstructive [*therapy]; Randomized Controlled Trials as Topic; Smoking [*therapy]

MeSH check words

Humans